

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI429469

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BETTER THERAPEUTICS, INC.	06/26/2024
Better Therapeutics Opco, Inc.	06/26/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Click Therapeutics, Inc.
<b>Street Address:</b>	80 White Street
<b>Internal Address:</b>	3rd Floor
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10013
<b>PROPERTY NUMBERS Total: 13</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15963994
Application Number:	15963999
Application Number:	17833623
Application Number:	17833625
Application Number:	17290204
Application Number:	18690246
Application Number:	62492065
Application Number:	62629644
Application Number:	62628842
Application Number:	62753811
Application Number:	62877781
Application Number:	63241434
Application Number:	63450954
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617)3424000

**Email:** scao@foley.com,ipdocketing@foley.com  
**Correspondent Name:** Mr. Austin J. Kim  
**Address Line 1:** 111 Huntington Avenue Suite 2500  
**Address Line 4:** Boston, MASSACHUSETTS 02199-7610

**ATTORNEY DOCKET NUMBER:** 109723-0361

**NAME OF SUBMITTER:** Xing Cao

**SIGNATURE:** Xing Cao

**DATE SIGNED:** 08/14/2024

**Total Attachments: 7**

source=Better-Click Acknowledgment of Acquisition#page1.tiff  
source=Better-Click Acknowledgment of Acquisition#page2.tiff  
source=Better-Click Acknowledgment of Acquisition#page3.tiff  
source=Better-Click Acknowledgment of Acquisition#page4.tiff  
source=Better-Click Acknowledgment of Acquisition#page5.tiff  
source=Better-Click Acknowledgment of Acquisition#page6.tiff  
source=Better-Click Acknowledgment of Acquisition#page7.tiff

## ACKNOWLEDGMENT OF ACQUISITION

ACKNOWLEDGMENT OF ACQUISITION (this "Acknowledgment"), dated as of June 26, 2024, is made by Better Therapeutics, Inc. of 548 Market Street 49404, San Francisco, CA 94104 USA and Better Therapeutics Opco, Inc. of 124 Washington Street, Foxboro, MA 02035 (collectively, "Better"), in favor of Click Therapeutics, Inc., a Delaware corporation of 80 White Street, 3rd Floor New York, NY 10013 USA ("Buyer").

WITNESSETH:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

WHEREAS, [REDACTED] Buyer has acquired the rights of Better in all assets of Better that constitute the Collateral [REDACTED] (the "Purchased Assets," as more specifically identified on Exhibit "A" attached hereto); and

WHEREAS, Buyer has requested that Better execute this Acknowledgment to make clear that Better's interest in the Purchased Assets has transferred to Buyer [REDACTED].

NOW THEREFORE, in consideration of the recitals set forth above:

1. Better acknowledges the sufficiency and validity of the Foreclosure Agreement and the Article 9 Private Sale, and that Buyer has acquired all rights, title, and interest in the Purchased Assets formerly held by Better.
2. Better acknowledges that all rights, title, and interest in the Purchased Assets has transferred to Buyer through the Foreclosure Sale Agreement and the Article 9 Private Sale, and that Buyer has acquired all rights, title, and interest in the Purchased Assets.
3. Buyer acknowledges that Buyer now has all rights, title, and interest in the Purchased Assets formerly held by Better.
4. Better acknowledges that this Acknowledgment can serve as evidence for recording the transfer of rights, title, and interest in the Purchased Assets in all jurisdictions from Better in favor Buyer.




6. A signed copy of this Acknowledgment delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Transfer Agreement.

The undersigned has caused this Acknowledgment to be executed as of the date first set forth above.



BETTER THERAPEUTICS, INC.

and


BETTER THERAPEUTICS OPCO, INC.


By:   
Name: Craig Jalbert  
Title: Director

*[to be completed by notary public]*

On this 26<sup>th</sup> day of June 2017, before me, ,  
the undersigned Notary Public, personally appeared   
on behalf of Better Therapeutics, Inc. and Better Therapeutics Opco, Inc. personally  
known to me (or proved to me on the basis of satisfactory evidence) to be the person  
whose name is subscribed to the within instrument, and acknowledged to me that the  
same was signed in their authorized capacity and that by this signature Better  
Therapeutics, Inc. and Better Therapeutics Opco, Inc. executed the instrument.

In witness whereof, I hereunto set my hand and official seal:


  
(notary signature)



(stamp)

The undersigned has caused this Acknowledgment to be executed as of the date first set forth above.


CLICK THERAPEUTICS, INC.


By:   
Name: Lisa Chen  
Title: Vice President of Finance

**[to be completed by notary public]**

On this 9 day of August, before me, Michael Santana,  
the undersigned Notary Public, personally appeared Lisa Chen  
on behalf of Click Therapeutics, Inc. personally known to me (or proved to me on the  
basis of satisfactory evidence) to be the person whose name is subscribed to the within  
instrument, and acknowledged to me that the same was signed in their authorized  
capacity and that by this signature Click Therapeutics, Inc. executed the instrument.

In witness whereof, I hereunto set my hand and official seal:

  
(notary signature)




**MICHAEL B SANTANA** (stamp)  
Notary Public  
State of New Jersey  
My Commission Expires Oct. 8, 2024  
I.D.# 50114421

## Exhibit "A"

### Purchased Assets

All of Borrowers' right, title and interest in and to the following personal property (capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the LSA):

All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including, for the avoidance of doubt, Intellectual Property, which includes, for avoidance of doubt, all rights in the patents and patent applications set forth on Schedule "1" attached hereto), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and all Borrower's Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. For the avoidance of doubt, the Collateral shall also include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property.



**Schedule "1"**

Patents and Patent Applications

Country	App No.	App. Date	Grant No.	Date
United States	15/963994	4/26/2018		
United States	15/963999	4/26/2018	11355228	6/7/2022
United States	17/833623	6/6/2022		
United States	17/833625	6/6/2022		
United States	17/290204	4/29/2021		
United States	18/690246	9/7/2022		
United States	62/492065	4/28/2017		
United States	62/629644	2/12/2018		
United States	62/628842	2/9/2018		
United States	62/753811	10/31/2018		
United States	62/877781	7/23/2019		
United States	63/241434	9/7/2021		
United States	63/450954	3/8/2023		
Belgium	18724423.1	11/13/2019	3628101	6/7/2023
Canada	3061725	10/28/2019		
Canada	3061729	10/28/2019		
Canada	3118297	4/29/2021		
Denmark	18724423.1	11/13/2019	3628101	6/7/2023
EPO	18724423.1	11/13/2019	3628101	6/7/2023
EPO	18724093.2	11/13/2019		
EPO	19809270.2	5/26/2021		
France	18724423.1	11/13/2019	3628101	6/7/2023
Germany	18724423.1	11/13/2019	3628101	6/7/2023
Ireland	18724423.1	11/13/2019	3628101	6/7/2023
Italy	18724423.1	11/13/2019	3628101	6/7/2023
PCT	PCT/US2018/029653	4/26/2018		
PCT	PCT /US2018/029654	4/26/2018		
PCT	PCT/US2019/059259	10/31/2019		
PCT	PCT/US2022/042797	9/7/2022		



Country	App No.	App. Date	Grant No.	Date
PCT	PCT/US2024/019259	3/8/2024		
Spain	18724423.1	11/13/2019	3628101	6/7/2023
Switzerland	18724423.1	11/13/2019	3628101	6/7/2023
United Kingdom	18724423.1	11/13/2019	3628101	6/7/2023